Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Top Analyst Reports for Johnson & Johnson, UnitedHealth, AT&T & Intel
by Mark Vickery
Today's Research Daily features new research reports on 17 major stocks, including Johnson & Johnson (JNJ), UnitedHealth (UNH), AT&T (T) and Intel (INTC).
Gilead (GILD) Beats on Q3 Earnings & Sales, Updates View
by Zacks Equity Research
Gilead's (GILD) third-quarter results beat estimates. However, persistent decline in HCV sales is disappointing.
New Batch of Q3 Earnings: AMZN, GOOGL, INTC & More
by Mark Vickery
Big afternoon of new quarterly earnings releases after the bell today, with some of the world's largest technology firms hitting the tape.
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 10.84% and 2.95%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Vertex (VRTX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex' (VRTX) Q3 gains on earnings and revenue beat with demand for its CF products rising high.
Bristol-Myers (BMY) Beats on Q3 Earnings, Raises EPS View
by Zacks Equity Research
Bristol-Myers (BMY) beats earnings estimates in the third quarter but misses sales expectation by a slight margin. Eliquis and Opdivo continue to record solid sales.
Sarepta (SRPT) Q3 Earnings & Sales Miss, Exondys 51 Sales Up
by Zacks Equity Research
Sarepta (SRPT) misses estimates on both counts in third-quarter 2018. However, Exondys 51 performs well on strong demand.
Healthcare ETFs to Buy Ahead of Q3 Earnings
by Sweta Killa
The positive estimate revisions suggest continued outperformance for the healthcare ETFs.
Alexion's (ALXN) Earnings Beat Estimates in Q3, Guidance Up
by Zacks Equity Research
Alexion (ALXN) beats earnings estimates and marginally misses sales estimates in the third quarter of 2018. The company also inks a deal to acquire Syntimmune for $1.2 billion.
Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release their third-quarter results on Oct 25. Let???s take a look at how these companies are poised ahead of their earnings release.
Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook
by Zacks Equity Research
Alkermes (ALKS) surpasses earnings and sales expectations in the third quarter of 2018 and raises its financial guidance for 2018.
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers
Will Gilead (GILD) HIV Sales Offset HCV Sales Decline in Q3?
by Zacks Equity Research
Gilead Sciences (GILD) is scheduled to report third-quarter results on Oct 25. We expect investors to focus on the strong HIV franchise and other pipeline updates.
Earnings Keep Pouring In: Global Week Ahead
by John Blank
So far, almost 90% of the firms have beaten analysts' earnings expectations. About 70% have beaten revenue expectations. This week, 156 S&P 500 firms release earnings.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $74.17, marking a -1.92% move from the previous day.
Gilead Sciences (GILD) Q3 Earnings Preview: What to Expect
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $73.59, marking a +1.5% move from the previous day.
Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates
by Zacks Equity Research
Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.
Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status
by Zacks Equity Research
Data presentations by leading sector players take center stage this week.
Gilead Sciences (GILD) Stock Moves -0.24%: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $76.24, marking a -0.24% move from the previous day.
Merck Reports Positive Efficacy Data from Phase III HIV Study
by Zacks Equity Research
Merck (MRK) reports positive data from the phase III DRIVE-AHEAD study, evaluating Delstrigo in treatment-naive adults with HIV-1 infection.
Gilead Announces Positive Data From Ongoing Biktarvy Study
by Zacks Equity Research
Gilead (GILD) reports positive data from an ongoing late stage study on HIV regimen, Biktarvy at 96 weeks.
J&J's Phase III Data Shows Switch to its HIV Drug Beneficial
by Zacks Equity Research
Data from the 96-week long phase III EMERALD study shows that switching to J&J's (JNJ) Symtuza maintains high virologic suppression.
Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors
by Zacks Equity Research
To boost its pipeline, Gilead (GILD) collaborates with HiFiBiO Therapeutics for the development of T-cell receptors.
Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs
by Zacks Equity Research
The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.